Yuhan's Leclaza to be cheaper than AstraZeneca's Tagrisso

10 June 2021 - The price of Yuhan's third generation epidermal growth factor receptor tyrosine kinase inhibitor for treating patients ...

Read more →

'Anticancer drug should extend life for 22 months to get insurance benefits'

27 May 2021 - A research team at National Cancer Center has found that the public believes that for an ...

Read more →

7 out of 10 Koreans want cheaper drug with same ingredient

27 May 2021 - Seven out of 10 Koreans want to lower the drug cost by choosing a cheaper generic ...

Read more →

Why is Tagrisso not reimbursable as first-line treatment in Korea?

24 May 2021 - Osimertinib (Tagrisso) has transformed the treatment paradigm for epidermal growth factor receptor mutation positive non-small cell ...

Read more →

‘Use effective drugs in early multiple myeloma to prevent relapse’

19 May 2021 - Multiple myeloma patients suffer frequent recurrences, and treatment response rates and response durations plummet along with ...

Read more →

‘More reimbursement needed for hepatocellular carcinoma’

14 May 2021 - “Unlike other cancers, hepatocellular carcinoma is mostly diagnosed non-invasively. But this has not been reflected in ...

Read more →

Eisai Korea to stop supply of blood cancer drug Symbenda this year

13 May 2021 - Symbenda (bendamustine), a treatment for blood cancer, is expected to become unavailable in Korea within this ...

Read more →

Gilead readies to sell anticancer drug Trodelvy in Korea

4 May 2021 - Gilead’s antibody-drug conjugate Trodelvy (sacituzumab govitecan) has won the Ministry of Food and Drug Safety’s designation ...

Read more →

Drug pricing policy in South Korea revised to ‘tiered pricing system’

14 April 2021 - The government announced a plan to restructure the generic drug pricing system with the main goal ...

Read more →

Petition filed for better access to haemophilia A drug

14 April 2021 - Parents of paediatric patients with haemophilia A are demanding the regulator to change the criteria for ...

Read more →

Janssen's prostate cancer drug gets reimbursement for mHSPC

6 April 2021 - Janssen said Tuesday that the government began providing health insurance benefits for its prostate cancer therapy ...

Read more →

Zytiga to get insurance benefit for primary therapy in metastatic hormone-sensitive prostate cancer

17 March 2021 - Janssen Korea’s prostate cancer drug Zytiga (ingredient: abiraterone acetate) will get expanded insurance benefits for the ...

Read more →

Primary dyslipidaemia drug Praluent gets insurance benefit

5 March 2021 - Sanofi-Aventis Korea’s primary dyslipidaemia treatment Praluent (alirocumab) has won health insurance benefits, the government said. ...

Read more →

Takeda’s drug for acute hereditary angioedema seizure to get larger benefits

24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for ...

Read more →

Anti-cancer drugs Ninlaro, Lutathera to get insurance benefits from March

24 February 2021 - Takeda’s multiple myeloma treatment Ninlaro (ixazomib) and Novartis’ neuroendocrine tumour drug Lutathera (lutetium oxodotreotide) will get ...

Read more →